Pharmaceutical business Amerigen Pharmaceuticals Limited revealed on Thursday the receipt of approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for the generic version of Adderall XR in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.
The company has received the US FDA's NDA approval for the generic version of Shire's Adderall XR (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, extended-release capsules) in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
In conjunction, the company's Amerigen Pharmaceuticals Inc US affiliate is currently selling an authorized generic version of Adderall XR, with a planned launch in the near future.
Additionally, the US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc, based in Lyndhurst, NJ.
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
Dr. Reddy's Laboratories Launches Tadalafil Tablets USP in the US Market
Sandoz unveils treprostinil injection in the US PAH market
Teva Launches of a Generic Version of Exjade Tablets for Oral Suspension in the United States
Teva launches generic version of EXJADE tablets for oral suspension in the US
Novo Nordisk and Teva Pharmaceuticals USA reach settlement on Victoza US patent litigation case
Mallinckrodt announces new chief financial officer
Novo Nordisk reaches settlement with Teva on US patent litigation case regarding Victoza
Perrigo wins US FDA tentative approval for generic Finacea Foam, 15%
US FDA approves new generic valsartan for high blood pressure and heart failure
Lannett Company signs contract with Elite Pharmaceuticals and SunGen Pharma
PDL BioPharma unveils authorised generic Tekturna (aliskiren) in the US
Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA